Article

Transition begins after Pfizer-Pharmacia merger

New York-Pfizer Inc. will invest $400 million to expand its New Jersey facilities and potentially add 1,300 jobs, but plans to close five research and development sites around the world-including two in the United States- and other former Pharmacia Corp. offices as it begins the difficult logistical transition of its $57 billion takeover.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) EyeCon 2025: Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
(mage credit: Ophthalmology Times) S. Robert Levine, MD, on the DRD Cure Accelerator: A global moonshot for retinal disease
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
Related Content
(Image credit: SeeWhatMatters)
August 22nd 2025

Q&A: AEVR's executive director on #SeeWhatMatters and safeguarding the National Eye Institute

3 Things You Should Know About the GA Pipeline
August 22nd 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: AdobeStock/InkInvent) FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy
August 22nd 2025

FDA clears path for US IDE study of Myra Vision’s titratable glaucoma therapy

Patient-Centered Treatment Strategies in the Management of nAMD and DME
August 22nd 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

(Image credit: AdobeStock/ipopba) Robotic precision: Elevating the state of laser cataract surgery
August 22nd 2025

Robotic precision: Elevating the state of laser cataract surgery

(Image credit: AdobeStock/zabhie) AI applications in cataract surgery: A surgeon’s perspective
August 22nd 2025

AI applications in cataract surgery: A surgeon’s perspective

© 2025 MJH Life Sciences

All rights reserved.